Jessica Hergert


Frontline masitinib combo delays progression in mCRPC with low metastatic involvement

September 13, 2021

Adding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels (ALP) of 250 IU/mL or less.